PMID: 7528094Dec 1, 1994Paper

Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic

Cancer Immunology, Immunotherapy : CII
I A HaagenB C de Gast

Abstract

We previously reported that a CD3 x CD19 bispecific antibody (bsAb) can induce efficient killing of tumour cells by preactivated T cells isolated from patients with B cell malignancy. For future intravenous application we investigated whether resting T cells from peripheral blood can be stimulated to proliferate and become cytotoxic with the CD3 x CD19 bsAb alone. Indeed peripheral blood mononuclear cells, isolated from healthy donors or patients with B cell malignancy, started to proliferate within 1 day in response to CD3 x CD19 bsAb. Within the same time span cytotoxic activity against CD19-positive tumour cells was already detectable. Maintenance of cytotoxic activity was seen during 3 days of culture but optimal lysis of the target cells then required fresh CD3 x CD19 bsAb in the cytotoxicity assay. Essentially the same results for proliferation and cytotoxicity were found when separated CD4-positive and CD8-positive T cells were activated by the bsAb in the presence of autologous monocytes. These results may be relevant for the in vivo application of the bsAb when used as immunotherapy in patients with B cell malignancy.

References

Jan 1, 1976·Journal of Immunological Methods·A SaxonR A Robins
Dec 1, 1992·European Journal of Immunology·M de BoerJ Reeder
Nov 1, 1991·Trends in Biotechnology·M W Fanger, P M Guyre
Aug 1, 1992·Immunobiology·D M SegalJ R Wunderlich
Feb 1, 1989·European Journal of Immunology·M ClarkH Waldmann
Jul 15, 1989·International Journal of Cancer. Journal International Du Cancer·W KnappA E von dem Borne
Apr 1, 1994·International Journal of Cancer. Journal International Du Cancer·C MaccalliA Anichini

❮ Previous
Next ❯

Citations

May 10, 2007·Cancer Immunology, Immunotherapy : CII·Freddy Tita-NwaMartin Kornacker
Sep 10, 2003·Current Opinion in Oncology·Jesús G Berdeja
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Jun 19, 2001·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·R RiesenbergH Lindhofer
Mar 20, 1998·International Journal of Cancer. Journal International Du Cancer·S RiedleM Zöller
Jun 2, 2009·Journal of Immunotherapy·Patrick BühlerUrsula Elsässer-Beile

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.